US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GRAIL, Inc.

48.49

-3.6700-7.04%

Post-market: 48.490.00000.00%19:59 EDT

Volume:735.35K

Turnover:35.82M

Market Cap:1.99B

PE:-4.36

High:52.29

Open:51.00

Low:47.55

Close:52.16

52wk High:118.84

52wk Low:20.44

Shares:41.02M

Float Shares:34.19M

Volume Ratio:0.99

T/O Rate:2.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-11.1105

EPS(LYR):-11.1105

ROE:-16.07%

ROA:-11.31%

PB:0.77

PE(LYR):-4.36

Loading ...

Overview Company News Filings

Stock Track | GRAIL, Inc. Plunges 47.50% in Pre-Market as Cancer Test Trial Misses Primary Endpoint

Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame. -- Barrons.com

Premarket Movers | Opendoor Surges 15%; AppLovin Jumps 5%; Copart Drops 7%; Akamai Sinks 9%; Grail Tumbles 47%

Tiger Newspress

Grail Inc reports results for the quarter ended December 31 - Earnings Summary

24H｜Opendoor up 15%; Applovin up 6%; GRAIL down 46%; Copart down 7%

Tiger Newspress

Stock Track | GRAIL, Inc. Plunges 47.49% in Post-Market as Key Cancer Test Trial Misses Primary Endpoint

Stocks to Watch: Akamai Technologies, Copart, Grail

Earnings Flash (GRAL) GRAIL Posts Q4 Loss $2.44 per Share, vs. FactSet Est of Loss of $2.70

MT Newswires Live

BUZZ-Grail slumps after Q4 results, cancer test misses main study goal

BRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met

Stock Track | GRAIL, Inc. Plunges 30.09% After-Hours as Key Trial Endpoint Misses Target

GRAIL FY 2025 net loss was USD 408.4 million, improving 80%

GRAIL Q4 EPS $(2.44) Beats $(2.73) Estimate, Sales $43.597M Miss $43.600M Estimate

Grail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses

Grail Inc: Primary Endpoint of Statistically Significant Combined Stage Iii-Iv Reduction Was Not Met

THOMSON REUTERS

Landmark Nhs-Galleri Trial Demonstrates a Substantial Reduction in Stage Iv Cancer Diagnoses, Increased Stage I and Ii Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate

THOMSON REUTERS

Grail Inc: Plans to Extend Trial's Follow up Period by 6-12 Months

THOMSON REUTERS

Grail Inc : TD Cowen Initiates Coverage With Hold Rating; Price Target $114

THOMSON REUTERS

Balancing Market Leadership and Regulatory Risk: Justifying a Hold Rating After a 450% Rally

Baird Initiates GRAIL at Outperform With $113 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GRAL/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GRAL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRAL\",,,,,undefined,":{"symbol":"GRAL","market":"US","secType":"STK","nameCN":"GRAIL, Inc.","latestPrice":48.49,"timestamp":1774641600000,"preClose":52.16,"halted":0,"volume":735350,"hourTrading":{"tag":"盘后","latestPrice":48.49,"preClose":48.49,"latestTime":"19:59 EDT","volume":24275,"amount":1176971.93,"timestamp":1774655978416,"change":0,"changeRate":0,"amplitude":0.003093},"delay":0,"changeRate":-0.07036042944785266,"floatShares":34193700,"shares":41020255,"eps":-11.110457,"marketStatus":"Market Closed","change":-3.67,"latestTime":"03-27 16:00:00 EDT","open":51,"high":52.29,"low":47.55,"amount":35822020.06075,"amplitude":0.090874,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-11.110457,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":52.16,"preHourTrading":{"tag":"盘前","latestPrice":51.4,"preClose":52.16,"latestTime":"09:25 EDT","volume":326,"amount":16822.717528,"timestamp":1774617900002,"change":-0.76,"changeRate":-0.014571,"amplitude":0.038727},"postHourTrading":{"tag":"盘后","latestPrice":48.49,"preClose":48.49,"latestTime":"19:59 EDT","volume":24275,"amount":1176971.93,"timestamp":1774655978416,"change":0,"changeRate":0,"amplitude":0.003093},"volumeRatio":0.98671,"impliedVol":0.975,"impliedVolPercentile":0.4821},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRAL\",,,,,undefined,":{"symbol":"GRAL","floatShares":34193700,"roa":"-11.31%","roe":"-16.07%","lyrEps":-11.110457,"volumeRatio":0.98671,"shares":41020255,"dividePrice":0,"high":52.29,"amplitude":0.090874,"preClose":52.16,"low":47.55,"week52Low":20.44,"pbRate":"0.77","psRate":"13.52","week52High":118.84,"institutionHeld":0,"latestPrice":48.49,"eps":-11.110457,"divideRate":0,"volume":735350,"delay":0,"ttmEps":-11.110457,"open":51,"prevYearClose":85.59,"prevWeekClose":46.84,"prevMonthClose":53.23,"prevQuarterClose":85.59,"fiveDayClose":46.84,"twentyDayClose":53.23,"sixtyDayClose":85.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GRAL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"GRAL","fiscalQuarterEnding":"2025/12","expectedEps":-3.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":-1.86},{"market":"US","date":"2025-11-12","symbol":"GRAL","fiscalQuarterEnding":"2025/09","expectedEps":-3.4,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-2.46},{"market":"US","date":"2025-08-12","symbol":"GRAL","fiscalQuarterEnding":"2025/06","expectedEps":-3.14,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-3.18},{"market":"US","date":"2025-05-13","symbol":"GRAL","fiscalQuarterEnding":"2025/03","expectedEps":-4.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-3.1},{"market":"US","date":"2025-02-20","symbol":"GRAL","fiscalQuarterEnding":"2024/12","expectedEps":-4.41,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"post","actualEps":-1.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GRAL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GRAL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":6,"updateTime":1773892800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GRAL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GRAL","date":"2026-03-27","current":-4.364357,"percent":0.231132,"low":-11.136928,"twenty":-6.370491,"median":-0.694504,"eighty":-0.275763,"high":-0.135365,"avg":-2.738793,"sd":3.404806,"marketCap":2139616500},"quantilePoints":[{"date":"2024-06-12","current":-0.243184,"twenty":-0.243184,"median":-0.243184,"eighty":-0.243184,"marketCap":362571424},{"date":"2024-06-28","current":-0.269888,"twenty":-0.264547,"median":-0.256536,"eighty":-0.248525,"marketCap":402385270},{"date":"2024-07-05","current":-0.275763,"twenty":-0.275763,"median":-0.271757,"eighty":-0.266328,"marketCap":411144316},{"date":"2024-07-12","current":-0.259385,"twenty":-0.273627,"median":-0.266328,"eighty":-0.249504,"marketCap":386725157},{"date":"2024-07-15","current":-0.263657,"twenty":-0.273022,"median":-0.264992,"eighty":-0.25148,"marketCap":393095372},{"date":"2024-08-02","current":-0.296236,"twenty":-0.274909,"median":-0.266328,"eighty":-0.253456,"marketCap":441668264},{"date":"2024-08-09","current":-0.310656,"twenty":-0.300615,"median":-0.272114,"eighty":-0.260667,"marketCap":463167741},{"date":"2024-08-16","current":-0.170902,"twenty":-0.29588,"median":-0.2706,"eighty":-0.248276,"marketCap":492749978},{"date":"2024-08-23","current":-0.178117,"twenty":-0.292284,"median":-0.264992,"eighty":-0.180551,"marketCap":513552907},{"date":"2024-08-30","current":-0.159595,"twenty":-0.28292,"median":-0.259385,"eighty":-0.170708,"marketCap":460148373},{"date":"2024-09-06","current":-0.145057,"twenty":-0.275763,"median":-0.247457,"eighty":-0.162201,"marketCap":418232023},{"date":"2024-09-13","current":-0.145918,"twenty":-0.275336,"median":-0.18151,"eighty":-0.152854,"marketCap":420715955},{"date":"2024-09-20","current":-0.149365,"twenty":-0.273627,"median":-0.178117,"eighty":-0.150075,"marketCap":430651682},{"date":"2024-09-27","current":-0.146457,"twenty":-0.273022,"median":-0.170741,"eighty":-0.146026,"marketCap":422268412},{"date":"2024-10-04","current":-0.135365,"twenty":-0.270458,"median":-0.165733,"eighty":-0.14454,"marketCap":390287790},{"date":"2024-10-11","current":-0.140319,"twenty":-0.269176,"median":-0.160133,"eighty":-0.142925,"marketCap":404570398},{"date":"2024-10-18","current":-0.152918,"twenty":-0.265794,"median":-0.156041,"eighty":-0.143463,"marketCap":440897901},{"date":"2024-10-25","current":-0.13978,"twenty":-0.263443,"median":-0.155556,"eighty":-0.143463,"marketCap":403017941},{"date":"2024-10-31","current":-0.146672,"twenty":-0.262589,"median":-0.153942,"eighty":-0.142688,"marketCap":422889395},{"date":"2024-11-08","current":-0.160456,"twenty":-0.259385,"median":-0.152918,"eighty":-0.142796,"marketCap":462632305},{"date":"2024-11-15","current":-0.250879,"twenty":-0.250879,"median":-0.154641,"eighty":-0.143442,"marketCap":531228205},{"date":"2024-11-22","current":-0.259924,"twenty":-0.250879,"median":-0.156041,"eighty":-0.143549,"marketCap":550380645},{"date":"2024-11-29","current":-0.277697,"twenty":-0.262044,"median":-0.156472,"eighty":-0.143635,"marketCap":588013510},{"date":"2024-12-06","current":-0.355611,"twenty":-0.27003,"median":-0.160025,"eighty":-0.14426,"marketCap":752993300},{"date":"2024-12-13","current":-0.329745,"twenty":-0.275763,"median":-0.161318,"eighty":-0.144928,"marketCap":698224042},{"date":"2024-12-20","current":-0.271984,"twenty":-0.27776,"median":-0.165841,"eighty":-0.145746,"marketCap":575917232},{"date":"2024-12-27","current":-0.308005,"twenty":-0.287312,"median":-0.170741,"eighty":-0.145918,"marketCap":652190984},{"date":"2025-01-03","current":-0.284362,"twenty":-0.289787,"median":-0.175532,"eighty":-0.146134,"marketCap":602125834},{"date":"2025-01-10","current":-0.280236,"twenty":-0.294514,"median":-0.180594,"eighty":-0.1465,"marketCap":593389633},{"date":"2025-01-17","current":-0.276189,"twenty":-0.293978,"median":-0.222157,"eighty":-0.146801,"marketCap":584821436},{"date":"2025-01-24","current":-0.412102,"twenty":-0.295346,"median":-0.234852,"eighty":-0.147318,"marketCap":872612048},{"date":"2025-01-31","current":-0.500013,"twenty":-0.298484,"median":-0.241319,"eighty":-0.14818,"marketCap":1058760325},{"date":"2025-02-07","current":-0.523498,"twenty":-0.307212,"median":-0.249504,"eighty":-0.148826,"marketCap":1108489468},{"date":"2025-02-14","current":-0.83436,"twenty":-0.31102,"median":-0.255132,"eighty":-0.149365,"marketCap":1766728591},{"date":"2025-02-21","current":-0.791697,"twenty":-0.321747,"median":-0.260916,"eighty":-0.149365,"marketCap":1604772870},{"date":"2025-02-28","current":-0.656882,"twenty":-0.34371,"median":-0.263657,"eighty":-0.149709,"marketCap":1331502572},{"date":"2025-03-07","current":-0.559345,"twenty":-0.359577,"median":-0.270244,"eighty":-0.149795,"marketCap":1133795978},{"date":"2025-03-14","current":-0.450152,"twenty":-0.414561,"median":-0.273627,"eighty":-0.15014,"marketCap":912460022},{"date":"2025-03-21","current":-0.465034,"twenty":-0.450921,"median":-0.275763,"eighty":-0.150484,"marketCap":942626791},{"date":"2025-03-28","current":-0.47791,"twenty":-0.468947,"median":-0.276427,"eighty":-0.150807,"marketCap":968726130},{"date":"2025-04-04","current":-0.416039,"twenty":-0.465703,"median":-0.277856,"eighty":-0.15113,"marketCap":843313720},{"date":"2025-04-11","current":-0.380338,"twenty":-0.459122,"median":-0.280236,"eighty":-0.151281,"marketCap":770947370},{"date":"2025-04-17","current":-0.443129,"twenty":-0.455455,"median":-0.281347,"eighty":-0.151562,"marketCap":898224019},{"date":"2025-04-25","current":-0.630246,"twenty":-0.466372,"median":-0.283965,"eighty":-0.151863,"marketCap":1277511821},{"date":"2025-05-02","current":-0.565758,"twenty":-0.478944,"median":-0.287218,"eighty":-0.15253,"marketCap":1146794916},{"date":"2025-05-09","current":-0.62862,"twenty":-0.498389,"median":-0.292296,"eighty":-0.15337,"marketCap":1274216573},{"date":"2025-05-16","current":-0.732698,"twenty":-0.51302,"median":-0.295346,"eighty":-0.153995,"marketCap":1402606531},{"date":"2025-05-23","current":-0.728564,"twenty":-0.527433,"median":-0.296725,"eighty":-0.154728,"marketCap":1394692362},{"date":"2025-05-30","current":-0.772349,"twenty":-0.542338,"median":-0.298484,"eighty":-0.155417,"marketCap":1478510603},{"date":"2025-06-06","current":-0.742094,"twenty":-0.562722,"median":-0.305137,"eighty":-0.155977,"marketCap":1420593278},{"date":"2025-06-13","current":-0.787758,"twenty":-0.602918,"median":-0.308322,"eighty":-0.156041,"marketCap":1508008868},{"date":"2025-06-20","current":-0.910282,"twenty":-0.617043,"median":-0.310838,"eighty":-0.156127,"marketCap":1742556049},{"date":"2025-06-27","current":-0.927946,"twenty":-0.628237,"median":-0.313683,"eighty":-0.156967,"marketCap":1776371133},{"date":"2025-07-03","current":-0.87796,"twenty":-0.640897,"median":-0.324667,"eighty":-0.158949,"marketCap":1680681639},{"date":"2025-07-11","current":-0.815382,"twenty":-0.656882,"median":-0.33641,"eighty":-0.159595,"marketCap":1560889904},{"date":"2025-07-18","current":-0.675007,"twenty":-0.694504,"median":-0.351643,"eighty":-0.160456,"marketCap":1292167904},{"date":"2025-07-25","current":-0.746416,"twenty":-0.703946,"median":-0.35847,"eighty":-0.160672,"marketCap":1428867181},{"date":"2025-08-01","current":-0.642872,"twenty":-0.704698,"median":-0.372061,"eighty":-0.161318,"marketCap":1230653229},{"date":"2025-08-08","current":-0.619382,"twenty":-0.703946,"median":-0.384644,"eighty":-0.164764,"marketCap":1185686362},{"date":"2025-08-15","current":-2.618835,"twenty":-0.718416,"median":-0.412102,"eighty":-0.165733,"marketCap":1160018171},{"date":"2025-08-22","current":-2.697774,"twenty":-0.721799,"median":-0.415789,"eighty":-0.165949,"marketCap":1194984536},{"date":"2025-08-29","current":-2.7759,"twenty":-0.732698,"median":-0.419718,"eighty":-0.170579,"marketCap":1229590423},{"date":"2025-09-05","current":-2.733582,"twenty":-0.742958,"median":-0.427076,"eighty":-0.170837,"marketCap":1210845568},{"date":"2025-09-12","current":-3.145369,"twenty":-0.751941,"median":-0.435395,"eighty":-0.172539,"marketCap":1393247431},{"date":"2025-09-19","current":-3.221867,"twenty":-0.757193,"median":-0.443129,"eighty":-0.177083,"marketCap":1427132362},{"date":"2025-09-26","current":-3.927439,"twenty":-0.772199,"median":-0.450236,"eighty":-0.179927,"marketCap":1739666779},{"date":"2025-10-03","current":-5.267781,"twenty":-0.790326,"median":-0.453995,"eighty":-0.180724,"marketCap":2333374029},{"date":"2025-10-10","current":-5.788618,"twenty":-0.792794,"median":-0.466707,"eighty":-0.18193,"marketCap":2564079942},{"date":"2025-10-17","current":-7.032117,"twenty":-0.810572,"median":-0.474733,"eighty":-0.214168,"marketCap":3114890311},{"date":"2025-10-24","current":-6.726125,"twenty":-0.834423,"median":-0.483801,"eighty":-0.232186,"marketCap":2979350587},{"date":"2025-10-31","current":-7.417862,"twenty":-0.86879,"median":-0.497307,"eighty":-0.23482,"marketCap":3285756878},{"date":"2025-11-07","current":-6.515349,"twenty":-0.90953,"median":-0.508594,"eighty":-0.23627,"marketCap":2885986787},{"date":"2025-11-14","current":-7.32206,"twenty":-1.284423,"median":-0.515869,"eighty":-0.238888,"marketCap":3243320953},{"date":"2025-11-21","current":-8.218834,"twenty":-2.622741,"median":-0.524768,"eighty":-0.242438,"marketCap":3338827399},{"date":"2025-11-28","current":-10.592844,"twenty":-2.668803,"median":-0.533066,"eighty":-0.245748,"marketCap":4303247596},{"date":"2025-12-05","current":-10.047321,"twenty":-2.733908,"median":-0.545714,"eighty":-0.248685,"marketCap":4081633659},{"date":"2025-12-12","current":-9.121802,"twenty":-2.773947,"median":-0.559678,"eighty":-0.249586,"marketCap":3705650118},{"date":"2025-12-19","current":-8.474563,"twenty":-3.023948,"median":-0.565758,"eighty":-0.250383,"marketCap":3442715024},{"date":"2025-12-26","current":-8.814736,"twenty":-3.115583,"median":-0.600672,"eighty":-0.254281,"marketCap":3580907004},{"date":"2026-01-02","current":-8.213077,"twenty":-3.191837,"median":-0.607471,"eighty":-0.259493,"marketCap":3336488466},{"date":"2026-01-09","current":-9.407758,"twenty":-3.756539,"median":-0.615248,"eighty":-0.260321,"marketCap":3821817142},{"date":"2026-01-16","current":-9.350183,"twenty":-4.63773,"median":-0.618067,"eighty":-0.262044,"marketCap":3798427809},{"date":"2026-01-23","current":-11.136928,"twenty":-5.050494,"median":-0.621638,"eighty":-0.262589,"marketCap":4524276801},{"date":"2026-01-30","current":-9.689876,"twenty":-5.381714,"median":-0.623725,"eighty":-0.263657,"marketCap":3936424878},{"date":"2026-02-06","current":-9.025844,"twenty":-5.92371,"median":-0.62862,"eighty":-0.266328,"marketCap":3666667895},{"date":"2026-02-13","current":-9.201448,"twenty":-6.490935,"median":-0.634416,"eighty":-0.269888,"marketCap":3738005363},{"date":"2026-02-20","current":-10.027753,"twenty":-6.738169,"median":-0.640672,"eighty":-0.270458,"marketCap":4094842980},{"date":"2026-02-27","current":-5.738328,"twenty":-6.59852,"median":-0.642551,"eighty":-0.271707,"marketCap":2343252016},{"date":"2026-03-06","current":-5.1161,"twenty":-6.525603,"median":-0.645131,"eighty":-0.273298,"marketCap":2089164448},{"date":"2026-03-13","current":-4.454105,"twenty":-6.495818,"median":-0.656882,"eighty":-0.273627,"marketCap":1818838106},{"date":"2026-03-20","current":-4.868977,"twenty":-6.467497,"median":-0.678025,"eighty":-0.275336,"marketCap":1988251759},{"date":"2026-03-27","current":-5.23965,"twenty":-6.370491,"median":-0.694504,"eighty":-0.275763,"marketCap":2139616500}],"updateTime":1774763681918},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GRAL\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1125018189","title":"Stock Track | GRAIL, Inc. Plunges 47.50% in Pre-Market as Cancer Test Trial Misses Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1125018189","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125018189?lang=en_us&edition=fundamental","pubTime":"2026-02-20 17:10","pubTimestamp":1771578659,"startTime":"0","endTime":"0","summary":"GRAIL, Inc.'s stock plummeted 47.50% in pre-market trading on Friday, following a significant decline in after-hours activity the previous session.The sharp drop came after the company announced that...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3aff9350c4e69a79fb71d36941587b32","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GRAL"],"gpt_icon":0},{"id":"2612130268","title":"Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2612130268","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612130268?lang=en_us&edition=fundamental","pubTime":"2026-02-20 17:06","pubTimestamp":1771578360,"startTime":"0","endTime":"0","summary":"Grail stock plunged around 50% in after-hours trading Thursday after the biotech company's cancer trial results disappointed investors.The biotech company said its multi-cancer screening test Galleri did not lead to a \"statistically significant reduction\" in stage 3 and 4 cancer in a U.K. National Health Service  trial of more than 142,000 people between the ages of 50 and 77.Galleri is a blood test, developed by Grail, to screen for a number of cancers before they become symptomatic.However, Grail said there was a \"favorable trend\" toward fewer stage 3 and 4 cancers in a group of 12 deadly cancers, as well as an increase in diagnoses of early stage cancer types that are typically detected later.But the trial ultimately failed to achieve its primary objective--a statistically significant reduction in late stage cancer. The shares tumbled 48% to $52.25 after the market closed -- the stock has jumped more than 200% over the past six months as of Thursday's close.Grail submitted a premark","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3aff9350c4e69a79fb71d36941587b32","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame. -- Barrons.com","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"1190854524","title":"Premarket Movers | Opendoor Surges 15%; AppLovin Jumps 5%; Copart Drops 7%; Akamai Sinks 9%; Grail Tumbles 47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190854524","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190854524?lang=en_us&edition=fundamental","pubTime":"2026-02-20 17:03","pubTimestamp":1771578186,"startTime":"0","endTime":"0","summary":"$Opendoor(OPEN)$ stock surged 15.1% as the residential real estate platform made progress in its transformation plan. Q4 revenue and adjusted EBITDA exceeded the Wall Street consensus...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"6ad57e01c0ccb742e176d1b2ef14bba2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKAM","GRAL","CPRT","APP","OPEN"],"gpt_icon":1},{"id":"2612035259","title":"Grail Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2612035259","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612035259?lang=en_us&edition=fundamental","pubTime":"2026-02-20 13:58","pubTimestamp":1771567125,"startTime":"0","endTime":"0","summary":"Grail Inc reports results for the quarter ended December 31 - Earnings SummaryGrail Inc GRAL.OQ reported a quarterly adjusted loss of $2.44 per share for the quarter ended December 31, higher than the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nL8N3ZG09B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"1108150265","title":"24H｜Opendoor up 15%; Applovin up 6%; GRAIL down 46%; Copart down 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108150265","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108150265?lang=en_us&edition=fundamental","pubTime":"2026-02-20 09:43","pubTimestamp":1771551803,"startTime":"0","endTime":"0","summary":"$Opendoor(OPEN)$ reported fourth-quarter revenue of $736 million, beating analyst estimates of $594.02 million, according to Benzinga Pro. The company reported a fourth-quarter loss of seven cents...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d714cbc4f821ed455fc61f96ceffe9c2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","BK4023","APP","BK4561","LU0323239441.USD","LU2087625088.SGD","LU2360106780.USD","OPEN","LU1861215975.USD","BK4562","IE00B19Z9P08.USD","BK4613","LU2298321311.HKD","BK4137","BK4539","CPRT","LU0323240290.USD","LU0823421333.USD","BK4079","BK4585","LU0097036916.USD","LU2092937221.SGD","LU0056508442.USD","LU2041044095.USD","LU1852331112.SGD","IE00B894F039.SGD","LU0353189763.USD","LU2250418816.HKD","IE0008368304.USD","IE00BZ9MQY76.HKD","BK4588","LU0353189680.USD","LU0823421416.USD","LU1861220033.SGD","LU2360108059.USD","GRAL","LU2290526834.HKD","LU2360107168.USD","BK4608","BK4139","LU2063271972.USD"],"gpt_icon":1},{"id":"1156140459","title":"Stock Track | GRAIL, Inc. Plunges 47.49% in Post-Market as Key Cancer Test Trial Misses Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1156140459","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156140459?lang=en_us&edition=fundamental","pubTime":"2026-02-20 09:02","pubTimestamp":1771549376,"startTime":"0","endTime":"0","summary":"GRAIL, Inc. (NASDAQ: GRAL) experienced a dramatic 24-hour plunge of 47.49% in post-market trading on Thursday. The severe drop in share price followed the release of pivotal clinical trial data and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GRAL"],"gpt_icon":0},{"id":"2612540234","title":"Stocks to Watch: Akamai Technologies, Copart, Grail","url":"https://stock-news.laohu8.com/highlight/detail?id=2612540234","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612540234?lang=en_us&edition=fundamental","pubTime":"2026-02-20 07:45","pubTimestamp":1771544700,"startTime":"0","endTime":"0","summary":"Akamai Technologies gave an adjusted earnings outlook that was lower than Wall Street expected. Shares fell 8% to $100.93 in after-hours trading Thursday.Copart's fiscal second-quarter financial results were below estimates. The stock fell 9% to $34.24 after the bell.Grail's cancer detection test failed to meet its primary endpoint during a trial. The stock dropped 48% to $53.13.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823421416.USD","LU2298321311.HKD","LU0823421333.USD","LU2360108059.USD","LU2092937221.SGD","BK4608","BK4585","BK4137","LU2041044095.USD","BK4116","LU2286300806.USD","BK4588","BK4554","IE0008368304.USD","LU0353189680.USD","BK4139","LU0323240290.USD","LU0323239441.USD","AKAM","LU2087625088.SGD","LU0097036916.USD","LU0353189763.USD","GRAL","LU1059921491.USD","CPRT"],"gpt_icon":0},{"id":"2612236815","title":"Earnings Flash (GRAL) GRAIL Posts Q4 Loss $2.44 per Share, vs. FactSet Est of Loss of $2.70","url":"https://stock-news.laohu8.com/highlight/detail?id=2612236815","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612236815?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:48","pubTimestamp":1771537724,"startTime":"0","endTime":"0","summary":"Earnings Flash (GRAL) GRAIL Posts Q4 Loss $2.44 per Share, vs. FactSet Est of Loss of $2.70","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GRAL"],"gpt_icon":0},{"id":"2612223235","title":"BUZZ-Grail slumps after Q4 results, cancer test misses main study goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2612223235","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612223235?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:43","pubTimestamp":1771537422,"startTime":"0","endTime":"0","summary":"BUZZ-Grail slumps after Q4 results, cancer test misses main study goal** Shares of cancer test maker Grail Inc GRAL.O fall 31.5% to $69.50 in aftermarket trading** Reports wider Q4 net loss of $99.2 million, an increase of $2.1 million or 2%     ** Reports Q4 revenue of $43.6 million, in line with analysts' estimates - data compiled by LSEG ** Co separately announces the results of a trial for its multi-cancer early detection test Galleri, which is used to screen for up to 50 types of cancer ** Says test did not meet the main goal of showing a statistically significant reduction in late-stage cancer diagnoses ** However, adds there was a positive trend in a predefined list of 12 deadly cancers; says the group that got the Galleri test had fewer late-stage cancer diagnoses after the first screening round** Shares of the company more than tripled last year ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL4N3ZF1XJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"2612235180","title":"BRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met","url":"https://stock-news.laohu8.com/highlight/detail?id=2612235180","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612235180?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:36","pubTimestamp":1771536988,"startTime":"0","endTime":"0","summary":"BRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not MetFeb 19 (Reuters) - Grail Inc GRAL.O:LANDMARK NHS-GALLERI TRIAL DEMONSTRATES A SUBSTANTIAL REDU","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA5XBTPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"1169766564","title":"Stock Track | GRAIL, Inc. Plunges 30.09% After-Hours as Key Trial Endpoint Misses Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1169766564","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169766564?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:33","pubTimestamp":1771536838,"startTime":"0","endTime":"0","summary":"GRAIL, Inc. (NASDAQ: GRAL) experienced a sharp decline of 30.09% in after-hours trading following the release of its fourth-quarter financial results and pivotal trial data.The stock's steep drop...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GRAL"],"gpt_icon":0},{"id":"2612238321","title":"GRAIL FY 2025 net loss was USD 408.4 million, improving 80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612238321","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612238321?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:03","pubTimestamp":1771535002,"startTime":"0","endTime":"0","summary":"GRAIL FY 2025 net loss was USD 408.4 million, improving 80%               GRAIL reported Q4 2025 total revenue of USD 43.6 million (+14% YoY), including U.S. Galleri revenue of USD 41.3 million (+31% ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL796wBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","BK4535","HMYY","GRAL","BK4534","BK4196","HIMY","BK4139","BK4548","BK4585","BK4121","BK4588","HIYY"],"gpt_icon":0},{"id":"2612238340","title":"GRAIL Q4 EPS $(2.44) Beats $(2.73) Estimate, Sales $43.597M Miss $43.600M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2612238340","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612238340?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:03","pubTimestamp":1771534982,"startTime":"0","endTime":"0","summary":"GRAIL (NASDAQ:GRAL) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.73) by 10.62 percent. This is a 15.57 percent increase over losses of $(2.89) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50734254/grail-q4-eps-2-44-beats-2-73-estimate-sales-43-597m-miss-43-600m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GRAIL Q4 EPS $(2.44) Beats $(2.73) Estimate, Sales $43.597M Miss $43.600M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2612238878","title":"Grail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses","url":"https://stock-news.laohu8.com/highlight/detail?id=2612238878","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612238878?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:01","pubTimestamp":1771534897,"startTime":"0","endTime":"0","summary":"Grail Inc. announced topline results from the randomized, controlled NHS-Galleri trial evaluating annual multi-cancer screening with its Galleri test in 142,000 participants aged 50–77 in England’s NHS over three years. The trial did not meet its primary endpoint of a statistically significant combined Stage III–IV reduction, but reported reductions in Stage IV diagnoses over sequential screening rounds  in a pre-specified group of 12 cancers, along with increased detection of Stage I–II cancers and a four-fold improvement in overall cancer detection rate versus standard screening alone. Detailed results have not yet been presented and are planned for submission for presentation at the ASCO 2026 Annual Meeting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL82JSK4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"2612388802","title":"Grail Inc: Primary Endpoint of Statistically Significant Combined Stage Iii-Iv Reduction Was Not Met","url":"https://stock-news.laohu8.com/highlight/detail?id=2612388802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612388802?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:01","pubTimestamp":1771534860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA5XBTPW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"2612238862","title":"Landmark Nhs-Galleri Trial Demonstrates a Substantial Reduction in Stage Iv Cancer Diagnoses, Increased Stage I and Ii Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2612238862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612238862?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:01","pubTimestamp":1771534860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA5XBTPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"2612238861","title":"Grail Inc: Plans to Extend Trial's Follow up Period by 6-12 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2612238861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612238861?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:01","pubTimestamp":1771534860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA5XBTPW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2612020984","title":"Grail Inc : TD Cowen Initiates Coverage With Hold Rating; Price Target $114","url":"https://stock-news.laohu8.com/highlight/detail?id=2612020984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612020984?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:31","pubTimestamp":1771504292,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nFWN3ZF14J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRAL"],"gpt_icon":0},{"id":"2612409287","title":"Balancing Market Leadership and Regulatory Risk: Justifying a Hold Rating After a 450% Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2612409287","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612409287?lang=en_us&edition=fundamental","pubTime":"2026-02-19 18:45","pubTimestamp":1771497922,"startTime":"0","endTime":"0","summary":"GRAIL Inc (GRAL) has received a new Hold rating, initiated by TD Cowen analyst, Daniel Brennan. Daniel Brennan has given his Hold rating due to a c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/balancing-market-leadership-and-regulatory-risk-justifying-a-hold-rating-after-a-450-rally-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/balancing-market-leadership-and-regulatory-risk-justifying-a-hold-rating-after-a-450-rally-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL","BK4139"],"gpt_icon":0},{"id":"2612545154","title":"Baird Initiates GRAIL at Outperform With $113 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2612545154","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612545154?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:29","pubTimestamp":1771331353,"startTime":"0","endTime":"0","summary":"GRAIL (GRAL) has an average rating of overweight and mean price target of $114.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","GRAL"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":145,"code":"91000000","status":"200"}]}}